Therapeutic regulation of gene expression in the inner ear using RNA interference

Advances in Oto-Rhino-Laryngology

Volumn 66, Issue , 2009, Pages 13-36

  Maeda, Yukihide ^a   Sheffield, Abraham M ^a   Smith, Richard J H ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HAMMERHEAD RIBOZYME; KCNQ4 PROTEIN, HUMAN; POTASSIUM CHANNEL KCNQ; RIBOZYME;

ANIMAL; ARTICLE; COCHLEA AQUEDUCT; GENE EXPRESSION REGULATION; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; INNER EAR DISEASE; PERCEPTION DEAFNESS; PHYSIOLOGY; RNA INTERFERENCE;

ANIMALS; COCHLEAR AQUEDUCT; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEARING LOSS, SENSORINEURAL; HUMANS; KCNQ POTASSIUM CHANNELS; LABYRINTH DISEASES; OLIGORIBONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA, CATALYTIC; TRANSFECTION;

EID: 67651209091     PISSN: 00653071     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000218205     Document Type: Article

References (106)

1. Van De Water TR, Lallemend F, Eshraghi AA, Ahsan S, He J, Guzman J, Polak M, Malgrange B, Lefebvre P P, Staecker H, Balkany TJ: Caspases, the enemy within, and their role in oxidative stress-induced apoptosis of inner ear sensory cells. Otol Neurotol 2004;25:627-632.
2. Maeda Y, Fukushima K, Nishizaki K, Smith RJ: In vitro and in vivo suppression of GJB2 expression by RNA interference. Hum Mol Genet 2005;14:1641- 1650.
3. Wilkie AO: The molecular basis of genetic dominance. J Med Genet 1994;31:89-98.
4. Denoyelle F, Lina-Granade G, Plauchu H, Bruzzone R, Chaïb H, Lévi-Acobas F, Weil D, Petit C: Connexin 26 gene linked to a dominant deafness. Nature 1998;393:319-320.
5. Rouan F, White T W, Brown N, Taylor AM, Lucke T W, Paul DL, Munro CS, Uitto J, Hodgins MB, Richard G: trans-dominant inhibition of connexin-43 by mutant connexin-26:implications for dominant connexin disorders affecting epidermal differentiation. J Cell Sci 2001;114:2105-2113.
6. Richard G, White T W, Smith LE, Bailey RA, Compton JG, Paul DL, Bale SJ: Functional defects of Cx26 resulting from a heterozygous missense mutation in a family with dominant deaf-mutism and palmoplantar keratoderma. Hum Genet 1998;103: 393-399.
7. Marziano NK, Casalotti SO, Portelli AE, Becker DL, Forge A: Mutations in the gene for connexin 26 (GJB2) that cause hearing loss have a dominant negative effect on connexin 30. Hum Mol Genet 2003;12:805-812.
8. Kubisch C, Schroeder BC, Friedrich T, Lütjohann B, El-Amraoui A, Marlin S, Petit C, Jentsch TJ: KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell 1999;96:437-446.
9. Coucke PJ, Van Hauwe P, Kelley PM, Kunst H, Schatteman I, Van Velzen D, Meyers J, Ensink RJ, Verstreken M, Declau F, Marres H, Kastury K, Bhasin S, McGuirt WT, Smith RJ, Cremers C W, Van de Heyning P, Willems PJ, Smith SD, Van Camp G: Mutations in the KCNQ4 gene are responsible for autosomal dominant deafness in four DFNA2 families. Hum Mol Genet 1999;8:1321-1328.
10. Kharkovets T, Hardelin J P, Safieddine S, Schweizer M, El-Amraoui A, Petit C, Jentsch TJ: KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci USA 2000;97:4333- 4338.
11. Van Laer L, Huizing EH, Verstreken M, van Zuijlen D, Wauters JG, Bossuyt PJ, Van de Heyning P, McGuirt WT, Smith RJ, Willems PJ, Legan PK, Richardson G P, Van Camp G: Nonsyndromic hearing impairment is associated with a mutation in DFNA5. Nat Genet 1998;20:194-197.
12. Yu C, Meng X, Zhang S, Zhao G, Hu L, Kong X: A 3-nucleotide deletion in the polypyrimidine tract of intron 7 of the DFNA5 gene causes nonsyndromic hearing impairment in a Chinese family. Genomics 2003;82:575-579.
13. Bischoff AM, Luijendijk M W, Huygen PL, van Duijnhoven G, De Leenheer EM, Oudesluijs GG, Van Laer L, Cremers FP, Cremers CW, Kremer H: A novel mutation identified in the DFNA5 gene in a Dutch family: a clinical and genetic evaluation. Audiol Neurootol 2004;9:34-46.
14. Gregan J, Van Laer L, Lieto LD, Van Camp G, Kearsey SE: A yeast model for the study of human DFNA5, a gene mutated in nonsyndromic hearing impairment. Biochim Biophys Acta 2003;1638:179- 186.
15. Van Laer L, Vrijens K, Thys S, Van Tendeloo VF, Smith RJ, Van Bockstaele DR, Timmermans J P, Van Camp G: DFNA5: hearing impairment exon instead of hearing impairment gene? J Med Genet 2004;41: 401-406.
16. Zhao YZ, Luo YK, Liang HD, Mei XG, Tang J, Lu CT, Zhang Y, Lin Q: Comparing transfection efficiency and safety for antisense oligodeoxyribonu- cleotide between phospholipids-based microbubbles and liposomes. J Drug Target 2006;14:687-693.
17. Juliano RL, Dixit VR, Kang H, Kim T Y, Miyamoto Y, Xu D: Epigenetic manipulation of gene expression: a toolkit for cell biologists. J Cell Biol 2005;169: 847-857.
18. Zamaratski E, Pradeepkumar PI, Chattopadhyaya J: A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. J Biochem Biophys Methods 2001;48:189- 208.
19. Kurreck J: Antisense technologies. Improvement through novel chemical modifications. Eur J Bio-chem 2003;270:1628-1644.
20. Gleave ME, Monia BP: Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-479.
21. Marwick C: First 'antisense' drug will treat CMV retinitis. JAMA 1998;280:871.
22. Dove A: Isis and antisense face crucial test without Novartis. Nat Biotechnol 2000;18:19.
23. Sandrasagra A, Leonard SA, Tang L, Teng K, Li Y, Ball HA, Mannion JC, Nyce JW: Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev 2002;12: 177-181.
24. Delprat B, Boulanger A, Wang J, Beaudoin V, Guitton MJ, Ventéo S, Dechesne CJ, Pujol R, Lavigne-Rebillard M, Puel JL, Hamel CP: Down-regulation of otospiralin, a novel inner ear protein, causes hair cell degeneration and deafness. J Neurosci 2002;22:1718-1725.
25. Morishita R, Gibbons GH, Horiuchi M, Nakajima M, Ellison KE, Lee W, Kaneda Y, Ogihara T, Dzau VJ: molecular delivery system for antisense oligo-nucleotides: enhanced effectiveness of antisense oli-gonucleotides by HVJ-liposome mediated transfer. J Cardiovasc Pharmacol Ther 1997;2:213-222.
26. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92:5855-5859.
27. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T: In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894-899.
28. Morishita R, Aoki M, Ogihara T: Does gene therapy become pharmacotherapy? Exp Physiol 2005;90: 307-313.
29. Watanabe K, Inai S, Jinnouchi K, Bada S, Hess A, Michel O, Yagi T: Nuclear-factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOS II) pathway damages the stria vascularis in cisplatin-treated mice. Anticancer Res 2002;22:4081-4085.
30. Jiang H, Sha SH, Schacht J: NF-kappaB pathway protects cochlear hair cells from aminoglycoside-induced ototoxicity. J Neurosci Res 2005;79:644- 651.
31. Nagy I, Monge A, Albinger-Hegyi A, Schmid S, Bodmer D: NF-kappaB is required for survival of immature auditory hair cells in vitro. J Assoc Res Otolaryngol 2005;1-9.
32. Kore AR, Vaish NK, Kutzke U, Eckstein F: Sequence specificity of the hammerhead ribozyme revisited; the NHH rule. Nucleic Acids Res 1998;26:4116- 4120.
33. Citti L, Rainaldi G: Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr Gene Ther 2005;5:11-24.
34. Davies G, Martin TA, Ye L, Lewis-Russell JM, Mason MD, Jiang WG: Phospholipase-C gamma-1 (PLCgamma-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells. Urol Oncol 2008;26:386-391.
35. Michienzi A, Rossi JJ: Intracellular applications of ribozymes. Methods Enzymol 2001;341:581-596.
36. Beigelman L, McSwiggen JA, Draper KG, Gonzalez C, Jensen K, Karpeisky AM, Modak AS, Matulic-Adamic J, DiRenzo AB, Haeberli P, Sweedler D, Tracz D, Grimm S, Wincott FE, Thackray VG, Usman N: Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 1995;270:25702-25708.
37. Usman N, Blatt LM: Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000;106:1197-1202.
38. Zinnen SP, Domenico K, Wilson M, Dickinson BA, Beaudry A, Mokler V, Daniher AT, Burgin A, Beigelman L: Selection, design, and characterization of a new potentially therapeutic ribozyme. RNA 2002;8:214-228.
39. Ciafre SA, Niola F, Wannenes F, Farace MG: An anti-VEGF ribozyme embedded within the adenoviral VA I sequence inhibits glioblastoma cell angiogenic potential in vitro. J Vasc Res 2004;41: 220-228.
40. Wright L, Kearney P: Current status of ribozymes as gene therapy agents for cancer. Cancer Invest 2001;19:495-509.
41. Suzuki T, Anderegg B, Ohkawa T, Irie A, Engebraaten O, Halks-Miller M, Holm PS, Curiel DT, Kashani-Sabet M, Scanlon KJ: Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther 2000;7:241- 248.
42. Tomari Y, Zamore PD: Perspective: machines for RNAi. Genes Dev 2005;19:517-529.
43. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002;296: 1000-1004.
44. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF: Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 2003;278:7108-7118.
45. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melano-gaster embryo lysate. EMBO J 2001;20:6877-6888.
46. McCaffrey A P, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA: Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003;21:639-644.
47. McCaffrey A P, Meuse L, Pham T T, Conklin DS, Hannon GJ, Kay MA: RNA interference in adult mice. Nature 2002;418:38-39.
48. Bitko V, Musiyenko A, Shulyayeva O, Barik S: Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005;11:50-55.
49. Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, Hellermann G, Behera S, Singam R, Lockey RF, Mohapatra SS: Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005;11:56-62.
50. Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G, Leenders F, Arnold W, Giese K, Klippel A, Kaufmann J: Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 2003;31:e127.
51. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL: RNAi suppresses polyglutamine-induced neu-rodegeneration in a model of spinocerebellar ataxia. Nat Med 2004;10:816-820.
52. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005;102: 5820-5825.
53. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811.
54. Hamilton AJ, Baulcombe DC: A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999;286:950-952.
55. Saxena S, Jonsson ZO, Dutta A: Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003;278:44312-44319.
56. Amarzguioui M, Holen T, Babaie E, Prydz H: Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2003;31:589- 595.
57. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
58. Kawamoto K, Oh SH, Kanzaki S, Brown N, Raphael Y: The functional and structural outcome of inner ear gene transfer via the vestibular and cochlear fluids in mice. Mol Ther 2001;4:575-585.
59. Staecker H, Praetorius M, Baker K, Brough DE. Vestibular hair cell regeneration and restoration of balance function induced by math1 gene transfer. Otol Neurotol 2007;28:223-231.
60. Lalwani AK, Han JJ, Walsh BJ, Zolotukhin S, Muzyczka N, Mhatre AN: Green fluorescent protein as a reporter for gene transfer studies in the cochlea. Hear Res 1997;114:139-147.
61. Cooper LB, Chan DK, Roediger FC, Shaffer BR, Fraser JF, Musatov S, Selesnick SH, Kaplitt MG: AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity. Otol Neurotol 2006;27:484-490.
62. Liu Y, Okada T, Nomoto T, Ke X, Kume A, Ozawa K, Xiao S: Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo. Exp Mol Med 2007;39:170-175.
63. Liu Y, Okada T, Shimazaki K, Sheykholeslami K, Nomoto T, Muramatsu S, Mizukami H, Kume A, Xiao S, Ichimura K, Ozawa K: Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea. Mol Ther 2008;16:474-480.
64. Han JJ, Mhatre AN, Wareing M, Pettis R, Gao WQ, Zufferey RN, Trono D, Lalwani AK: Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene transfer vector. Hum Gene Ther 1999;10:1867-1873.
65. Jero J, Tseng CJ, Mhatre AN, Lalwani AK: A surgical approach appropriate for targeted cochlear gene therapy in the mouse. Hear Res 2001;151:106-114.
66. Jero J, Mhatre AN, Tseng CJ, Stern RE, Coling DE, Goldstein JA, Hong K, Zheng WW, Hoque AT, Lalwani AK: Cochlear gene delivery through an intact round window membrane in mouse. Hum Gene Ther 2001;12:539-548.
67. Yamasoba T, Yagi M, Roessler BJ, Miller JM, Raphael Y: Inner ear transgene expression after adenoviral vector inoculation in the endolymphatic sac. Hum Gene Ther 1999;10:769-774.
68. Ballana E, Wang J, Venail F, Estivill X, Puel JL, Arbonès ML, Bosch A: Efficient and specific transduction of cochlear supporting cells by adeno-asso-ciated virus serotype 5. Neurosci Lett 2008;442: 134-139.
69. Kanzaki S, Shiotani A, Inoue M, Hasegawa M, Ogawa K: Sendai virus vector-mediated transgene expression in the cochlea in vivo. Audiol Neurootol 2007;12:119-126.
70. Staecker H, Li D, O'Malley BW Jr, Van De Water TR: Gene expression in the mammalian cochlea: a study of multiple vector systems. Acta Otolaryngol 2001;121:157-163.
71. Luebke AE, Steiger JD, Hodges BL, Amalfitano A: A modified adenovirus can transfect cochlear hair cells in vivo without compromising cochlear function. Gene Ther 2001;8:789-794.
72. Wareing M, Mhatre AN, Pettis R, Han JJ, Haut T, Pfister MH, Hong K, Zheng W W, Lalwani AK: Cationic liposome mediated transgene expression in the guinea pig cochlea. Hear Res 1999;128:61-69.
73. Derby ML, Sena-Esteves M, Breakefield XO, Corey DP: Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. Hear Res 1999;134:1-8.
74. Li Duan M, Bordet T, Mezzina M, Kahn A, Ulfendahl M: Adenoviral and adeno-associated viral vector mediated gene transfer in the guinea pig cochlea. Neuroreport 2002;13:1295-1299.
75. Goycoolea ML, Lundman L: Round window membrane. Structure function and permeability: a review. Microscop Res Tech 1997;36:201-211.
76. Suzuki M, Yamasoba T, Suzukawa K, Kaga K: Adenoviral vector gene delivery via the round window membrane in guinea pigs. Neuroreport 2003; 14:1951-1955.
77. Pushparaj PN, H'ng SC, Melendez AJ: Refining siRNA in vivo transfection: silencing SPHK1reveals its key role in C5a-induced inflammation in vivo. Int J Biochem Cell Biol 2008;40:1817-1825.
78. Réjiba S, Wack S, Aprahamian M, Hajri A: K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 2007; 98:1128-1136.
79. Hickerson RP, Smith FJ, Reeves RE, Contag CH, Leake D, Leachman SA, Milstone LM, McLean WH, Kaspar RL: Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 2008;128:594-605.
80. Arnold AS, Tang YL, Qian K, Shen L, Valencia V, Phillips MI, Zhang YC: Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia. J Hypertens 2007;25:197- 205.
81. Christoph T, Grünweller A, Mika J, Schäfer MK, Wade EJ, Weihe E, Erdmann VA, Frank R, Gillen C, Kurreck J: Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun 2006;350:238-243.
82. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-958.
83. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC: A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002;99:5515-5520.
84. Yu JY, DeRuiter SL, Turner DL: RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002;99:6047-6052.
85. Wang D, Zhong ZY, Li MX, Xiang DB, Li ZP: Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo. Cancer Sci 2007;98:1993-2001.
86. Xia H, Mao Q, Paulson HL, Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002;20:1006-1010.
87. Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P: Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423-428.
88. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, Wong LF, Bilsland LG, Greensmith L, Kingsman SM, Mitrophanous KA, Mazarakis ND, Azzouz M: Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005; 11:429-433.
89. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003;9:210-216.
90. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P, Wishart W, Hall J: siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004; 32:e49.
91. Tan PH, Yang LC, Shih HC, Lan KC, Cheng JT: Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 2005;12:59-66.
92. Lingor P, Koeberle P, Kugler S, Bahr M: Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. Brain 2005;128:550-558.
93. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Rao JS: Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004;23:4681-4689.
94. Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, Honma K, Nagahara S, Hanai K, Sano A, Kato T, Terada M, Ochiya T: Atelocollagen- mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004;32:e109.
95. Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW, Whang EE: Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg 2004;240:667-676.
96. Sumimoto H, Yamagata S, Shimizu A, Miyoshi H, Mizuguchi H, Hayakawa T, Miyagishi M, Taira K, Kawakami Y: Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 2005;12:95- 100.
97. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12:461- 466.
98. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-351.
99. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E: Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003;8:769-776.
100. Klein C, Bock CT, Wedemeyer H, Wüstefeld T, Locarnini S, Dienes H P, Kubicka S, Manns M P, Trautwein C: Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003;125:9-18.
101. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004;101:8676-8681.
102. Tompkins SM, Lo CY, Tumpey TM, Epstein SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA 2004;101:8682-8686.
103. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-178.
104. Hamar P, Song E, Kokeny G, Chen A, Ouyang N, Lieberman J: Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 2004;101:14883- 14888.
105. Ying RS, Zhu C, Fan XG, Li N, Tian XF, Liu HB, Zhang BX: Hepatitis B virus is inhibited by RNA interference in cell culture and in mice. Antiviral Res 2007;73:24-30.
106. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, Kim SW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P: T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134:577-586.